Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter ...

A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...

Despite the results, the company is still in a strong position to continue leading the weight loss space. Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...